lymphoma, after initiation of immunosuppressives. [6] Systemic hepatosplenic T-cell lymphoma was also reported with immunomodulators and biologics in a patient with Crohn's disease. [7] It is reported in literature that there is a definite risk of developing lymphoma in the patients of psoriasis. [8] There was a suggestion of genetic linkage in the pathogenesis of psoriasis and CTCL. [9] Hence, we conclude that CTCL can not only be masquerading as psoriasis both clinically and histopathologically but also there can be some causal linkage. CTCL was reported in patients of psoriasis who were treated with biologicals such as etanercept [10] and efalizumab. [11] Keeping in mind the above discussion and the context of our patient, we strongly suggest that a biopsy for histopathology should be considered in cases of recalcitrant psoriasis, especially before starting biological therapy.
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Sir, Cutaneous leishmaniasis (CL) is a parasitic disease caused by the intracellular protozoan Leishmania and transmitted by the bite of an infected sand fly belonging to the genus Phlebotomus or Lutzomyia. There are estimated 12 million cases worldwide, with 1.5 million new cases being reported annually. In India, the disease has been reported from the hot and dry areas of Rajasthan and Gujarat, with indigenous cases being reported from Kerala, Assam, Haryana, and now recently from Himachal Pradesh, where it is mainly caused by Leishmania tropica. [1, 2] There has been an upsurge in the incidence of CL in this part of the country over the past few years. Most of our patients hailed from two districts of the valley -Kupwara and Baramulla, all located along the northwestern frontier of Kashmir valley and with Kupwara sharing its border with Pakistan-administered Kashmir. Unlike the rest of the valley which is known for cool temperature during summers rarely exceeding 35°C, these areas possess the distinction of having warmer and dry climate. All the affected patients came from low socioeconomic strata, dwelling in mud houses with no proper protection from insect exposure. Moreover, predominant outdoor occupations such as animal rearing and farming accounted for the exposed fraction of population to high risk of the disease.
Lesions mainly occur on the exposed parts, and noduloulcerative type is the predominant clinical type observed in our patients though other atypical forms are also being encountered.
One noteworthy feature observed in our preliminary study was a positive "tin tack" sign which could be elicited in four of our patients in the lesions over face, after obtaining an informed consent from them. The lesions showed a remarkable morphology and evolution from slow growing, painless papules that enlarged to form erythematous, infiltrated plaques with overlying adherent scale and crust.
These patients ranged in age from 16 to 52 years. Two were females and two males. The lesions of CL were localized to the face. Two patients had a solitary plaque over nose; two had similar lesion over chin. Average duration of lesions varied from 6 to 8 months and lesional size ranged from 1 to 6 cm. A closer look at the lesions revealed the appearance of small horny plugs attached to the under surface of the scale removed from the affected site, resembling "tin tacks" or "carpet tacks" penetrating the underlying skin [ Figures 1 and 2] . Diagnosis of the disease was made clinically as well by tissue smears and histopathology. Slit-skins smear for Leishman-Donovan (LD) bodies was positive in all four patients. Histopathology showed hyperkeratosis, dilated follicular plugs, epithelioid cell granuloma interspersed with occasional giant cells. LD bodies could be demonstrated in four patients in tissue smears [ Figure 3a and b]. However, due to unavailability of modern diagnostic furnishings such as polymerase chain reaction, species identification was not possible in our setup.
All the four patients were treated with sodium stibogluconate, injected intralesionally till blanching of lesion; an alternate day schedule for 3 days in a week in the outpatient clinic which produced consistently reliable response in all patients and no major side effects was noted. Although a positive "tin tack" sign has been a well-portrayed feature of discoid lupus erythematosus (DLE) and has also been reported in localized pemphigus foliaceus, [3] seborrheic dermatitis, [4] postirradiation scalp scales, [5] cutaneous B-cell lymphoma, [6] and lichen planus associated with captopril. [7] Our preliminary study highlights the presence of this sign in a significant number of patients in CL, which to the best of our knowledge has not been reported in the literature previously. Thus, a positive tin tack sign should not be considered exclusively as a feature of DLE but can be seen in other disorders also. Moreover, being a nonendemic area, unearthing the "tic tack" sign in CL from Kashmir valley, assumes all the more epidemiological importance.
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Nil. Sir, We report a case of 50-year-old woman, who developed aggravation of her preexisting stable psoriasis vulgaris on introducing atorvastatin to control her recently detected hypercholesterolemia, the aggravation seemed to be aided by concomitant cyclosporine (CsA).
Our patient had intermittent psoriasis vulgaris for the past 3 years. Oral methotrexate and topical clobetasol and calcipotriol were of slight help, but she responded best with CsA 100 mg twice daily which she took regularly for the past 10 months and her disease was stable with no recurrence or aggravation since then. She is also a known case of hypertension (on telmisartan 40 mg/day) and diabetes mellitus (on metformin, glicazide, and 
